Profound Medical Corp. (PROF) Stock Score, Valuation & Financial Research
Profound Medical Corp. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 35/100.
Quick answer for PROF
Profound Medical Corp. currently has a Wall Street Score of 35/100. The stored market price is $5.97. Its financial score is 43/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Profound Medical Corp. does
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
PROF financial snapshot
- Wall Street Score:
- 35/100
- Current price:
- $5.97
- Market capitalization:
- $216.9M
- Revenue:
- $18.7M
- Net income:
- $-38.8M
- Free cash flow:
- $-39.1M
- Cash:
- $50.5M
- Total debt:
- $7.5M
- EPS:
- -1.43
- Financial score:
- 43/100
- Valuation score:
- 0/100
- Revenue score:
- 35/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-39.1M, showing cash burn in the current stored period.
- The balance sheet shows $50.5M of cash versus $7.5M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 43/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research PROF
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.